Northwire Canada EditionFriday, October 16, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4186.00 +0.4% SILVER 57.26 +0.2% COPPER 6.57 +0.2% OIL 99.00 +1.1% PALLADIUM 1115.75 −1.1% MSV 0.570 +0.0% CCMM 0.520 +7.2% MON 0.385 −6.1% OMI 0.250 +0.0% BUFF 0.800 +2.6% FEO 0.640 −1.5% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% BVA 0.780 +2.6% ONAU 0.530 +1.9% FMR 0.225 +0.0% GSVR 0.347 +2.2% PHNM 0.345 +1.5% SLG 5.60 −1.9% CASA 0.060 +0.0% GOLD 4186.00 +0.4% SILVER 57.26 +0.2% COPPER 6.57 +0.2% OIL 99.00 +1.1% PALLADIUM 1115.75 −1.1% MSV 0.570 +0.0% CCMM 0.520 +7.2% MON 0.385 −6.1% OMI 0.250 +0.0% BUFF 0.800 +2.6% FEO 0.640 −1.5% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% BVA 0.780 +2.6% ONAU 0.530 +1.9% FMR 0.225 +0.0% GSVR 0.347 +2.2% PHNM 0.345 +1.5% SLG 5.60 −1.9% CASA 0.060 +0.0%

Healthcare

Page 62
  1. Feb 12, 2026 · 07:00 · MSCL

    Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy

    Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy

    01
  2. Feb 12, 2026 · 06:31 · CHS

    Comprehensive Healthcare Systems Announces Closing of First Tranche of Private Placement

    Comprehensive Healthcare Systems Announces Closing of First Tranche of Private Placement

    02
  3. Feb 12, 2026 · 03:45 · 4565

    Nxera Pharma to Receive $1.8 Million Milestone Payment from Centessa Pharmaceuticals

    Nxera Pharma to Receive $1.8 Million Milestone Payment from Centessa Pharmaceuticals

    03
  4. Feb 12, 2026 · 03:37 · 4565

    Nxera Pharma Licenses GPCR-targeted Program to Newly Founded Spin-out Company

    Nxera Pharma Licenses GPCR-targeted Program to Newly Founded Spin-out Company

    04
  5. Feb 12, 2026 · 02:15 · VPT

    Ventripoint to issue 291,344 shares for interest

    Ventripoint to issue 291,344 shares for interest

    05
  6. Feb 11, 2026 · 17:31 · MDP

    Medexus Announces Fiscal Q3 2026 Results, Driven by Continued Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection

    Medexus Announces Fiscal Q3 2026 Results, Driven by Continued Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection

    06
  7. Feb 11, 2026 · 04:27 · OTC

    Ocumetics enters forbearance deal with debentureholders

    Ocumetics enters forbearance deal with debentureholders

    07
  8. Feb 10, 2026 · 17:48 · HELP

    Cybin appoints Cola CEO

    Cybin appoints Cola CEO

    08
  9. Feb 10, 2026 · 17:15 · CRDL

    Cardiol sees phase 2 Archer study results published

    Cardiol sees phase 2 Archer study results published

    09
  10. Feb 10, 2026 · 17:09 · THRM

    Therma portfolio co. completes FIH stroke cohort

    Therma portfolio co. completes FIH stroke cohort

    10
  11. Feb 10, 2026 · 16:50 · OTC

    Ocumetics Announces Forbearance Agreement for $4 Million Secured Convertible Debentures and Provides LIFE Offering Update

    Ocumetics Announces Forbearance Agreement for $4 Million Secured Convertible Debentures and Provides LIFE Offering Update

    11
  12. Feb 10, 2026 · 16:13 · MBX

    Microbix adds CAP as QAP customer

    Microbix adds CAP as QAP customer

    12
  13. Feb 10, 2026 · 16:04 · NRX

    NurExone Biologic Advances Manufacturing and Regulatory Roadmap with Independent Batch Consistency Results for Exosome Production

    NurExone Biologic Advances Manufacturing and Regulatory Roadmap with Independent Batch Consistency Results for Exosome Production

    13
  14. Feb 10, 2026 · 11:28 · VIVI

    Tempramed launches products in Israel's Super-Pharm

    Tempramed launches products in Israel's Super-Pharm

    14
← Newer Older →